Table 4.
Patient symptoms evaluated at baseline (visit 1), after the PPI test (visit 2) and at the end of the 12-week lansoprazole treatment period (visit 3)
|
Visit 1 |
Visit 2 |
Visit 3 |
||||
| VAS | Score | VAS | Score | VAS | Score | |
| Lansoprazole | 8 (7.5-9.5) | 9 (8-9) | 2 (1.5-5.5)b | 4 (3-7)a | 1 (0-4.5)b | 3 (0-6.5)b |
| (30 mg/d) | ||||||
| (n = 17) | ||||||
| Lansoprazole | 9 (8-9) | 8 (7-9) | 2 (1-6.5)b | 3.5 (3-7)a | 1 (0-5)b | 3 (0-6.25)b |
| (60 mg/d) | ||||||
| (n = 18) | ||||||
Data expressed as median (25%-75% quartiles).
b
P < 0.001 vs visit 1;
a
P < 0.005 vs visit 1.